ZA200207206B - Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates. - Google Patents

Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates. Download PDF

Info

Publication number: ZA200207206B
Authority: ZA; South Africa
Prior art keywords: uricase; poly; conjugate; peg; ethylene glycol
Prior art date: 2000-02-10

Application number

ZA200207206A

Other languages

English (en)

Inventor

Mark G P Saifer

Merry R Sherman

Williams L David

Original Assignee

Mountain View Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2002-09-09

Publication date

2003-05-06

2002-09-09 Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals

2003-05-06 Publication of ZA200207206B publication Critical patent/ZA200207206B/en

Links

108010092464 Urate Oxidase Proteins 0.000 title claims description 272
229940005267 urate oxidase Drugs 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title description 17
230000002163 immunogen Effects 0.000 title description 9
229920000642 polymer Polymers 0.000 title description 7
-1 poly(ethylene oxide) Polymers 0.000 claims description 75
238000000034 method Methods 0.000 claims description 27
230000005847 immunogenicity Effects 0.000 claims description 26
229920001223 polyethylene glycol Polymers 0.000 claims description 25
102000004190 Enzymes Human genes 0.000 claims description 18
108090000790 Enzymes Proteins 0.000 claims description 18
229940088598 enzyme Drugs 0.000 claims description 18
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 17
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 17
238000000149 argon plasma sintering Methods 0.000 claims description 16
210000004185 liver Anatomy 0.000 claims description 16
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 14
229940116269 uric acid Drugs 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 12
241001504519 Papio ursinus Species 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 7
241000196324 Embryophyta Species 0.000 claims description 6
210000001124 body fluid Anatomy 0.000 claims description 6
239000010839 body fluid Substances 0.000 claims description 6
230000002538 fungal effect Effects 0.000 claims description 6
238000004255 ion exchange chromatography Methods 0.000 claims description 6
230000000813 microbial effect Effects 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 6
241000283690 Bos taurus Species 0.000 claims description 5
125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims description 5
238000001542 size-exclusion chromatography Methods 0.000 claims description 5
241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
238000005259 measurement Methods 0.000 claims description 4
241000186074 Arthrobacter globiformis Species 0.000 claims description 3
241000228197 Aspergillus flavus Species 0.000 claims description 3
241000235646 Cyberlindnera jadinii Species 0.000 claims description 3
241000255313 Drosophila pseudoobscura Species 0.000 claims description 3
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 3
244000068988 Glycine max Species 0.000 claims description 3
235000010469 Glycine max Nutrition 0.000 claims description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
210000004899 c-terminal region Anatomy 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
238000000108 ultra-filtration Methods 0.000 claims description 2
241001599018 Melanogaster Species 0.000 claims 1
230000006320 pegylation Effects 0.000 description 67
108010068701 Pegloticase Proteins 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 17
230000001751 uricolytic effect Effects 0.000 description 16
238000002835 absorbance Methods 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
241000699670 Mus sp. Species 0.000 description 14
230000000694 effects Effects 0.000 description 13
238000004458 analytical method Methods 0.000 description 10
238000003556 assay Methods 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
230000021615 conjugation Effects 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 7
238000005516 engineering process Methods 0.000 description 6
238000011084 recovery Methods 0.000 description 6
238000011725 BALB/c mouse Methods 0.000 description 5
241001415846 Procellariidae Species 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000007423 decrease Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000003442 weekly effect Effects 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000255601 Drosophila melanogaster Species 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229910021538 borax Inorganic materials 0.000 description 2
OZMJXAQDMVDWBK-UHFFFAOYSA-N carbamic acid;ethyl carbamate Chemical compound NC(O)=O.CCOC(N)=O OZMJXAQDMVDWBK-UHFFFAOYSA-N 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000036963 noncompetitive effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000002688 persistence Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000010339 sodium tetraborate Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
201000001431 Hyperuricemia Diseases 0.000 description 1
206010051364 Hyperuricosuria Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229960000458 allantoin Drugs 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
238000001818 capillary gel electrophoresis Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000013578 denaturing buffer Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000036515 potency Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000011800 void material Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200207206A 2000-02-10 2002-09-09 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates. ZA200207206B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/501,730 US6783965B1 (en)	2000-02-10	2000-02-10	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (1)

Publication Number	Publication Date
ZA200207206B true ZA200207206B (en)	2003-05-06

Family

ID=23994789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200207206A ZA200207206B (en)	2000-02-10	2002-09-09	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates.

Country Status (27)

Country	Link
US (3)	US6783965B1 (fr)
EP (3)	EP2305819B1 (fr)
JP (2)	JP5165826B2 (fr)
KR (3)	KR20070092329A (fr)
CN (2)	CN100491532C (fr)
AT (1)	ATE463576T1 (fr)
AU (3)	AU4997501A (fr)
BE (1)	BE2013C045I2 (fr)
BR (1)	BRPI0108386B8 (fr)
CA (1)	CA2398679C (fr)
CY (3)	CY1110142T1 (fr)
CZ (1)	CZ304864B6 (fr)
DE (1)	DE60141742D1 (fr)
DK (3)	DK2305819T3 (fr)
ES (2)	ES2524153T3 (fr)
FR (1)	FR13C0036I2 (fr)
HU (1)	HU227127B1 (fr)
IL (3)	IL151065A0 (fr)
LU (1)	LU92237I2 (fr)
MX (1)	MXPA02007545A (fr)
NZ (1)	NZ520434A (fr)
PL (1)	PL208064B1 (fr)
PT (2)	PT1254237E (fr)
RU (3)	RU2281954C2 (fr)
TW (2)	TWI322184B (fr)
WO (1)	WO2001059078A2 (fr)
ZA (1)	ZA200207206B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PL202799B1 (pl) *	1998-08-06	2009-07-31	Mountain View Pharmaceuticals	Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6783965B1 (en) *	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
JP2002524053A (ja)	1998-08-06	2002-08-06	デューク・ユニバーシティー	尿酸オキシダーゼ
ES2245114T3 (es)	1998-08-06	2005-12-16	Mountain View Pharmaceuticals, Inc.	Conjugados de peg-oxidasa de urato y su uso.
US20060188971A1 (en) *	1998-08-06	2006-08-24	Duke University	Urate oxidase
AU2002345938A1 (en)	2001-06-28	2003-03-03	Mountain View Pharmaceuticals, Inc.	Polymer stabilized proteinases
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
WO2003103475A2 (fr)	2002-06-07	2003-12-18	Dyax Corp.	Prevention et reduction de la perte sanguine
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) *	2002-12-26	2007-08-31	Маунтин Вью Фамэсьютикэлс, Инк.	ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
JP2007530440A (ja) *	2003-05-12	2007-11-01	アフィーマックス・インコーポレイテッド	新規ポリ（エチレングリコール）修飾化合物およびその用途
WO2004100997A2 (fr)	2003-05-12	2004-11-25	Affymax, Inc.	Nouveau fragment espaceur de composes peptidiques modifies par du poly(ethylene glycol)
SI1625156T1 (sl) *	2003-05-12	2013-02-28	Affymax, Inc.	Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
PT1663281E (pt) *	2003-08-29	2014-03-17	Dyax Corp	Inibidores de proteases poli-peguilados
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (fr) *	2004-11-11	2006-06-15	Affymax, Inc.	Nouveaux peptides se liant au recepteur de l'erythropoietine
EA200700990A1 (ru) *	2004-11-11	2008-04-28	Афимакс, Инк.	Новые пептиды, которые связывают рецептор эритропоэтина
CA2602654A1 (fr) *	2005-04-05	2006-10-12	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
HUE052976T2 (hu)	2005-04-11	2021-06-28	Horizon Pharma Rheumatology Llc	Urát-oxidáz variáns formái és azok alkalmazása
WO2006110761A2 (fr)	2005-04-11	2006-10-19	Savient Pharmaceuticals, Inc.	Forme de variante d'oxydase d'urate et utilisation associee
US20080159976A1 (en) *	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
TWI418564B (zh) *	2005-04-11	2013-12-11	Savient Pharmaceuticals Inc	利用陽離子界面活性劑之蛋白質純化
WO2006125452A1 (fr) *	2005-05-23	2006-11-30	Universite De Geneve	Nanoparticules superparamagnetiques injectables destinees a un traitement par hyperthermie et a la formation d'un implant
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
CN101622270B (zh) *	2006-04-12	2014-01-01	萨文特医药公司	用阳离子表面活性剂纯化蛋白质的方法
CA2696208A1 (fr) *	2007-08-21	2009-02-26	Genzyme Corporation	Traitement par des inhibiteurs de la kallikreine
CA2744235A1 (fr)	2009-01-06	2010-07-15	Dyax Corp.	Traitement de la mucosite par des inhibiteurs de kallikreine
HUP1200205A3 (en)	2009-06-25	2012-09-28	Savient Pharmaceuticals	Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
EP3459564B1 (fr)	2010-01-06	2021-10-27	Takeda Pharmaceutical Company Limited	Protéines de liaison de kallicréine plasmatique
US8940861B2 (en)	2010-04-08	2015-01-27	Georgia Tech Research Corporation	Variants of ancestral uricases and uses thereof
CA2823776A1 (fr)	2011-01-06	2012-07-12	Dyax Corp.	Proteines se liant a la kallikreine plasmatique
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
DK3003358T3 (da)	2013-06-07	2021-06-21	Allena Pharmaceuticals Inc	Sammensætninger og anordninger til dialyse
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003360A2 (fr)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Composés thérapeutiquement actifs et leurs méthodes d'utilisation
CN105593215B (zh)	2013-07-11	2019-01-15	安吉奥斯医药品有限公司	用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (fr)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
KR20240010105A (ko)	2014-03-14	2024-01-23	아지오스 파마슈티컬스 아이엔씨.	치료적으로 활성인 화합물의 약제학적 조성물
IL295414B2 (en)	2014-03-27	2026-02-01	Takeda Pharmaceuticals Co	Compositions and methods for treating macular edema due to diabetes
CN107614007B (zh)	2015-05-15	2022-03-25	免疫医疗有限责任公司	改进的尿酸酶序列和治疗方法
PT3362066T (pt)	2015-10-15	2021-11-16	Celgene Corp	Terapia de combinação para tratar malignidades
SG11201803088PA (en)	2015-10-15	2018-05-30	Agios Pharmaceuticals Inc	Combination therapy for treating malignancies
AU2016366557B2 (en)	2015-12-11	2024-01-25	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN110234340A (zh)	2016-11-11	2019-09-13	好利恩风湿病制药有限责任公司	泼尼松和尿酸酶分子的组合疗法及其用途
US20200237881A1 (en)	2019-01-30	2020-07-30	Horizon Pharma Rheumatology Llc	Reducing immunogenicity to pegloticase
JP2020530282A (ja)	2017-07-07	2020-10-22	アレナファーマシューティカルズ，インコーポレイテッド	組換えウリカーゼ酵素
WO2019183292A1 (fr)	2018-03-20	2019-09-26	Rubius Therapeutics, Inc.	Systèmes de cellules thérapeutiques et méthodes de traitement de l'hyperuricémie et de la goutte
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
CN109055260B (zh) *	2018-08-08	2021-11-09	淮海工学院	弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
US12121566B2 (en)	2019-01-30	2024-10-22	Horizon Therapeutics Usa, Inc.	Methods for treating gout
CN118497161A (zh) *	2019-05-10	2024-08-16	重庆派金生物科技有限公司	聚乙二醇修饰的尿酸氧化酶
US12528880B2 (en)	2020-01-13	2026-01-20	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
MX2023001740A (es)	2020-08-10	2023-04-05	Horizon Therapeutics Usa Inc	Metodos de tratamiento de la gota.
CN114181917B (zh) *	2022-02-14	2022-06-03	潍坊华卓生物科技有限公司	一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) *	2022-05-06	2023-11-14	江苏恰瑞生物科技有限公司	一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en)	2023-08-03	2025-04-08	Jeff R. Peterson	Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279486C (fr)
FR6301M (fr) *	1967-03-29	1968-09-09
US3616231A (en)	1968-11-14	1971-10-26	Boehringer Mannheim Gmbh	Process for the production of uricase
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5599189A (en)	1979-01-22	1980-07-28	Mihama Hisaharu	Modified uricase free from antigenicity and its preparation
JPS55135590A (en)	1979-04-05	1980-10-22	Mihama Hisaharu	Modified asparaginase and uricase and their preparation
CH657141A5 (de)	1980-07-01	1986-08-15	Hoffmann La Roche	Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en)	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
DE3126759A1 (de)	1981-07-07	1983-01-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) *	1985-06-26	1991-02-07	Cetus Corp	Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en)	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de)	1986-03-10	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) *	1986-04-23	1987-03-10	Mihama Hisaharu	修飾ウリカ−ゼ
JPH085506B2 (ja) *	1986-08-25	1996-01-24	日東製器株式会社	缶容器
DD279489A1 (de)	1986-12-11	1990-06-06	Leuna Werke Veb	Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5955336A (en) *	1988-08-17	1999-09-21	Toyo Boseki Kabushiki Kaisha	DNA sequence for uricase and manufacturing process of uricase
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en)	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja)	1989-11-01	1991-06-25	Sumitomo Pharmaceut Co Ltd	修飾ペプチドおよびその製造方法
SU1730145A1 (ru) *	1990-05-04	1992-04-30	Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности	Способ стабилизации уриказы
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5653974A (en)	1990-10-18	1997-08-05	Board Of Regents,The University Of Texas System	Preparation and characterization of liposomal formulations of tumor necrosis factor
DK0575545T3 (da) *	1991-03-15	2003-09-15	Amgen Inc	Pegylering af polypeptider
WO1993000951A1 (fr)	1991-07-02	1993-01-21	Inhale, Inc.	Procede et dispositf d'administration de medicaments en aerosol
WO1994019007A1 (fr)	1993-02-16	1994-09-01	Enzon, Inc.	Compositions proteiques d'inactivation du ribosome presentant une antigenicite reduite
AU6586394A (en) *	1993-04-22	1994-11-08	Celtrix Pharmaceuticals, Inc.	Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (fr)	1993-06-21	1995-01-05	Enzon, Inc.	Synthese de peptides conjuges modifies, sur des sites specifiques
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
KR960705579A (ko)	1993-11-10	1996-11-08	에릭에스. 딕커	개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
FI972443L (fi)	1994-12-07	1997-06-09	Novo Nordisk As	Polypeptidi, jonka allergeenisuus on vähentynyt
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
FR2733914B1 (fr) *	1995-05-11	1997-08-01	Sanofi Sa	Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en)	1995-06-07	1998-12-29	Chiron Corporation	Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja)	1995-12-05	1997-06-17	Asahi Chem Ind Co Ltd	ウリカーゼを生産する実質上純粋な微生物
CA2277757C (fr)	1997-01-15	2008-09-16	Phoenix Pharmacologics, Inc.	Facteur de necrose des tumeurs modifie
EP1500661A1 (fr) *	1998-06-01	2005-01-26	Genetech, Inc.	Séparation de monomères de protéines d'aggrégats par chromatographie d'échange ionique
ES2245114T3 (es)	1998-08-06	2005-12-16	Mountain View Pharmaceuticals, Inc.	Conjugados de peg-oxidasa de urato y su uso.
PL202799B1 (pl)	1998-08-06	2009-07-31	Mountain View Pharmaceuticals	Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6783965B1 (en) *	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
JP2002524053A (ja)	1998-08-06	2002-08-06	デューク・ユニバーシティー	尿酸オキシダーゼ
US6425448B1 (en)	2001-01-30	2002-07-30	Cdx Gas, L.L.P.	Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en)	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
EP3005545A1 (fr)	2013-05-24	2016-04-13	Zentrum Mikroelektronik Dresden AG	Convertisseur continu - continu numérique non pwm

2000
- 2000-02-10 US US09/501,730 patent/US6783965B1/en not_active Expired - Lifetime
2001
- 2001-02-06 TW TW090102540A patent/TWI322184B/zh not_active IP Right Cessation
- 2001-02-06 TW TW097145974A patent/TW200914617A/zh unknown
- 2001-02-07 AU AU4997501A patent/AU4997501A/xx active Pending
- 2001-02-07 CZ CZ2002-2982A patent/CZ304864B6/cs not_active IP Right Cessation
- 2001-02-07 CA CA2398679A patent/CA2398679C/fr not_active Expired - Lifetime
- 2001-02-07 EP EP10180428.4A patent/EP2305819B1/fr not_active Expired - Lifetime
- 2001-02-07 ES ES10180428.4T patent/ES2524153T3/es not_active Expired - Lifetime
- 2001-02-07 EP EP10158016.5A patent/EP2196538B1/fr not_active Expired - Lifetime
- 2001-02-07 EP EP01923265A patent/EP1254237B1/fr not_active Expired - Lifetime
- 2001-02-07 NZ NZ520434A patent/NZ520434A/en not_active IP Right Cessation
- 2001-02-07 KR KR1020077018682A patent/KR20070092329A/ko not_active Ceased
- 2001-02-07 CN CNB018077501A patent/CN100491532C/zh not_active Expired - Lifetime
- 2001-02-07 RU RU2002120486/13A patent/RU2281954C2/ru not_active IP Right Cessation
- 2001-02-07 DK DK10180428.4T patent/DK2305819T3/en active
- 2001-02-07 PL PL358539A patent/PL208064B1/pl unknown
- 2001-02-07 KR KR1020087024272A patent/KR101054247B1/ko not_active Expired - Lifetime
- 2001-02-07 MX MXPA02007545A patent/MXPA02007545A/es active IP Right Grant
- 2001-02-07 DE DE60141742T patent/DE60141742D1/de not_active Expired - Lifetime
- 2001-02-07 PT PT01923265T patent/PT1254237E/pt unknown
- 2001-02-07 RU RU2006107110/13A patent/RU2352354C2/ru active
- 2001-02-07 IL IL15106501A patent/IL151065A0/xx unknown
- 2001-02-07 DK DK01923265.1T patent/DK1254237T3/da active
- 2001-02-07 PT PT101804284T patent/PT2305819E/pt unknown
- 2001-02-07 AT AT01923265T patent/ATE463576T1/de active
- 2001-02-07 JP JP2001558218A patent/JP5165826B2/ja not_active Expired - Lifetime
- 2001-02-07 AU AU2001249975A patent/AU2001249975B2/en not_active Revoked
- 2001-02-07 DK DK10158016.5T patent/DK2196538T3/en active
- 2001-02-07 HU HU0204544A patent/HU227127B1/hu active Protection Beyond IP Right Term
- 2001-02-07 KR KR1020027010189A patent/KR100884724B1/ko not_active Expired - Lifetime
- 2001-02-07 WO PCT/US2001/040069 patent/WO2001059078A2/fr not_active Ceased
- 2001-02-07 ES ES01923265T patent/ES2343105T3/es not_active Expired - Lifetime
- 2001-02-07 BR BRPI0108386A patent/BRPI0108386B8/pt not_active Application Discontinuation
- 2001-02-07 CN CN2009101278530A patent/CN101735991B/zh not_active Expired - Lifetime
2002
- 2002-08-05 IL IL151065A patent/IL151065A/en active Protection Beyond IP Right Term
- 2002-09-09 ZA ZA200207206A patent/ZA200207206B/en unknown
2007
- 2007-08-03 US US11/882,750 patent/US7927852B2/en not_active Expired - Fee Related
2008
- 2008-08-11 IL IL193365A patent/IL193365A/en active IP Right Grant
2009
- 2009-02-06 RU RU2009104003/10A patent/RU2557318C9/ru active
- 2009-09-02 AU AU2009212900A patent/AU2009212900B2/en not_active Expired
2010
- 2010-06-29 CY CY20101100597T patent/CY1110142T1/el unknown
2011
- 2011-04-12 JP JP2011088663A patent/JP5341945B2/ja not_active Expired - Lifetime
- 2011-04-13 US US13/085,793 patent/US8921064B2/en not_active Expired - Fee Related
2013
- 2013-07-03 LU LU92237C patent/LU92237I2/fr unknown
- 2013-07-03 BE BE2013C045C patent/BE2013C045I2/fr unknown
- 2013-07-04 FR FR13C0036C patent/FR13C0036I2/fr active Active
- 2013-07-04 CY CY2013028C patent/CY2013028I1/el unknown
2015
- 2015-02-09 CY CY20151100129T patent/CY1117264T1/el unknown

Also Published As

Publication number	Publication date
CA2398679A1 (fr)	2001-08-16
JP2011188861A (ja)	2011-09-29
CZ20022982A3 (cs)	2003-01-15
ES2524153T3 (es)	2014-12-04
BR0108386B1 (pt)	2017-10-31
AU2001249975B2 (en)	2006-06-08
TWI322184B (en)	2010-03-21
RU2006107110A (ru)	2007-09-20
AU4997501A (en)	2001-08-20
CZ304864B6 (cs)	2014-12-17
RU2009104003A (ru)	2010-08-20
TW200914617A (en)	2009-04-01
MXPA02007545A (es)	2002-12-13
WO2001059078A3 (fr)	2002-03-07
CA2398679C (fr)	2015-11-17
HUP0204544A3 (en)	2007-05-02
EP2305819A1 (fr)	2011-04-06
CY2013028I2 (el)	2015-11-04
EP2196538A1 (fr)	2010-06-16
CY1117264T1 (el)	2017-04-26
AU2009212900A1 (en)	2009-10-01
LU92237I2 (fr)	2013-09-03
PL208064B1 (pl)	2011-03-31
PT1254237E (pt)	2010-06-07
HK1143989A1 (en)	2011-01-21
DK1254237T3 (da)	2010-07-19
HK1056742A1 (zh)	2004-02-27
IL151065A0 (en)	2003-04-10
CY1110142T1 (el)	2015-01-14
KR20020087934A (ko)	2002-11-23
RU2557318C2 (ru)	2015-07-20
IL151065A (en)	2008-12-29
KR101054247B1 (ko)	2011-08-08
CN1423699A (zh)	2003-06-11
RU2352354C2 (ru)	2009-04-20
ATE463576T1 (de)	2010-04-15
IL193365A0 (en)	2009-02-11
CY2013028I1 (el)	2015-11-04
DE60141742D1 (de)	2010-05-20
EP1254237A2 (fr)	2002-11-06
KR20080098686A (ko)	2008-11-11
EP2196538B1 (fr)	2014-10-01
CN101735991B (zh)	2013-09-11
KR20070092329A (ko)	2007-09-12
US8921064B2 (en)	2014-12-30
ES2343105T3 (es)	2010-07-23
BRPI0108386B8 (pt)	2021-05-25
JP2003521937A (ja)	2003-07-22
HU227127B1 (en)	2010-07-28
FR13C0036I2 (fr)	2014-05-16
US7927852B2 (en)	2011-04-19
PT2305819E (pt)	2015-06-01
RU2557318C9 (ru)	2015-09-10
EP2305819B1 (fr)	2014-11-12
ES2343105T8 (es)	2013-07-15
HUP0204544A2 (en)	2003-05-28
CN100491532C (zh)	2009-05-27
BR0108386C1 (pt)	2011-12-20
US6783965B1 (en)	2004-08-31
CN101735991A (zh)	2010-06-16
BR0108386A (pt)	2002-10-29
KR100884724B1 (ko)	2009-02-19
RU2281954C2 (ru)	2006-08-20
DK2305819T3 (en)	2015-01-05
FR13C0036I1 (fr)	2013-08-09
WO2001059078A2 (fr)	2001-08-16
IL193365A (en)	2011-08-31
NZ520434A (en)	2004-05-28
US20110287466A1 (en)	2011-11-24
EP1254237B1 (fr)	2010-04-07
BE2013C045I2 (fr)	2020-06-24
JP5341945B2 (ja)	2013-11-13
HK1155203A1 (en)	2012-05-11
JP5165826B2 (ja)	2013-03-21
US20080057048A1 (en)	2008-03-06
AU2009212900B2 (en)	2011-12-08
DK2196538T3 (en)	2015-01-05
HK1144701A1 (en)	2011-03-04
PL358539A1 (en)	2004-08-09

Publication	Publication Date	Title
AU2001249975B2 (en)	2006-06-08	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20180223263A1 (en)	2018-08-09	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU2001249975A1 (en)	2001-11-01	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU2006203252B8 (en)	2009-06-18	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1155203B (en)	2015-09-25	Conjugates prepared with aggregate-free proteins
HK1143989B (en)	2015-08-14	Conjugates prepared with aggregate-free proteins
HK1155080A (en)	2012-05-11	Isolated tetrameric uricase
HK1141738B (en)	2013-11-22	Peg-urate oxidase conjugates and use thereof